has vaccine antigen
vaccinated in route
immunizes host
Homo sapiens
spike glycoprotein (SARS-CoV-2)
intramuscular route
AdimrSC-2f
vaccine
A SARS-CoV-2 protein subunit vaccine developed by Adimmune Corporation. AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
https://go.drugbank.com/drugs/DB16436
NCT04522089
https://www.smartpatients.com/trials/NCT04522089
Philip Huang, Oliver He
COVID-19 subunit vaccine